Compare Liquidia Corporation Common Stock (LQDA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs 10X Genomics Inc — how do they compare? Liquidia Corporation Common Stock trades at $34.2 (market cap $3.04B), while 10X Genomics Inc trades at $72.37 (market cap $9.53B). The key difference: 10X Genomics Inc is far larger — about 3.1× Liquidia Corporation Common Stock's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| LQDA | TXG | |
|---|---|---|
Market Cap | $3.04B | $9.53B |
Volume | 21,111,778 | 4,138,224 |
Sector | Health | Health |
52-Week High | $91.03 | $97.74 |
52-Week Low | $22.02 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $2.94B | $9.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG (10x Genomics) trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with a significant reduction in net losses (-$43.54M in 2025 vs. -$183M in 2024) and positive operating cash flow of $136.05M. Recent news highlights strong demand for its new Atera spatial biology platform and a patent victory. However, valuation metrics remain elevated with a P/S of 14.86 and EV/EBITDA of 230.71.
The outlook is cautiously optimistic. Analyst consensus is mixed with a $83.30 price target implying 16% upside, but execution on Atera commercialization and sustained margin improvement are critical. Key risks include high valuation, competitive pressures, and reliance on instrument sales growth. The stock offers growth exposure to spatial biology but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
